Validation of the revised prognostic model in the NCRI-AML18 trial. Patient characteristics (A) with the molecular and cytogenetic landscape at diagnosis of the validation cohort (B) and OS after 1 year for patients in first relapse according to risk categories of the revised prognostic model (C). Supplemental Figure 9B shows the 4-year OS rates for patients at their first relapse, categorized by the revised prognostic model. Restratification of patients from HOVON-SAKK (D) and GOELAMS model (E) to the revised prognostic model in the validation cohort. abn, abnormality in; ck, complex karyotype (annotated according to the 2022 ELN risk classification); CRi, CR with incomplete count recovery; del, deletion in; inv, inversion of; mk, monosomal karyotype; m, monosomy; t, translocation of.